Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
6.40
+0.12 (1.91%)
May 2, 2025, 4:00 PM EDT - Market closed
Coya Therapeutics Revenue
In the year 2024, Coya Therapeutics had annual revenue of $3.55M, down -40.79%. Coya Therapeutics had revenue of $1.95K in the quarter ending December 31, 2024, a decrease of -99.97%.
Revenue (ttm)
$3.55M
Revenue Growth
-40.79%
P/S Ratio
27.31
Revenue / Employee
$444,258
Employees
8
Market Cap
107.04M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.55M | -2.45M | -40.79% |
| Dec 31, 2023 | 6.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.19B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
COYA News
- 7 days ago - Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release - Seeking Alpha
- 8 days ago - Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia - Business Wire
- 11 days ago - Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death) - Business Wire
- 4 weeks ago - Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025 - Business Wire
- 5 weeks ago - Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program - Business Wire
- 6 weeks ago - Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results - Business Wire
- 2 months ago - Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations - Business Wire
- 3 months ago - Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD - Seeking Alpha